Deccan Medisales Profile
Key Indicators
- Authorised Capital ₹ 2.10 M
as on 16-11-2024
- Paid Up Capital ₹ 2.10 M
as on 16-11-2024
- Company Age 13 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 18.18%
(FY 2023)
- Profit 22.59%
(FY 2023)
- Ebitda 18.53%
(FY 2023)
- Net Worth 15.67%
(FY 2023)
- Total Assets -0.35%
(FY 2023)
About Deccan Medisales
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.10 M and a paid-up capital of Rs 2.10 M, as per Ministry of Corporate Affairs (MCA) records.
Satya Kammila, Phani Ramella, and Paidiwar Srinivas serve as directors at the Company.
- CIN/LLPIN
U51397KA2011PTC059204
- Company No.
059204
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jun 2011
- Date of AGM
12 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Deccan Medisales?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satya Kammila  | Director | 29-Sep-2021 | Current |
| Phani Ramella | Director | 18-Jan-2012 | Current |
| Paidiwar Srinivas | Director | 27-Aug-2019 | Current |
Financial Performance of Deccan Medisales.
Deccan Medisales Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 18.18% increase. The company also saw a substantial improvement in profitability, with a 22.59% increase in profit. The company's net worth Soared by an impressive increase of 15.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deccan Medisales?
In 2023, Deccan Medisales had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dureleg Manufacturing Private LimitedActive 10 years 11 monthsSatya Kammila and Paidiwar Srinivas are mutual person
- Sai Sridhar Pharma Private LimitedActive 17 years 2 months
Satya Kammila, Phani Ramella and 1 more are mutual person
- Wynclark Pharmaceuticals Private LimitedActive 17 years 10 months
Satya Kammila and Paidiwar Srinivas are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Deccan Medisales?
Unlock and access historical data on people associated with Deccan Medisales, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deccan Medisales, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deccan Medisales's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
